Phasing out PFAS: Next steps for medical device manufacturers
Per- and polyfluoroalkyl substances (PFAS) are at the heart of a huge regulatory debate in Europe, with major consequences on the horizon for medical device OEMs. What should companies do next to ensure a secure supply of their products long into the future?
